ID: ALA2216902

Max Phase: Preclinical

Molecular Formula: C28H36N8O4S

Molecular Weight: 580.72

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)c1nc2ccccc2n1-c1nc(N2CCOCC2)c2nc(OC3CN(C4CCS(=O)(=O)CC4)C3)n(C)c2n1

Standard InChI:  InChI=1S/C28H36N8O4S/c1-18(2)24-29-21-6-4-5-7-22(21)36(24)27-31-25-23(26(32-27)34-10-12-39-13-11-34)30-28(33(25)3)40-20-16-35(17-20)19-8-14-41(37,38)15-9-19/h4-7,18-20H,8-17H2,1-3H3

Standard InChI Key:  XRLOEZGWBZHADC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 580.72

Molecular Weight (Monoisotopic): 580.2580

AlogP: 2.30

#Rotatable Bonds: 6

Polar Surface Area: 120.50

Molecular Species: NEUTRAL

HBA: 12

HBD: 0

#RO5 Violations: 2

HBA (Lipinski): 12

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 5.44

CX LogP: 2.90

CX LogD: 2.89

Aromatic Rings: 4

Heavy Atoms: 41

QED Weighted: 0.34

Np Likeness Score: -1.29

References

1. Cushing TD, Metz DP, Whittington DA, McGee LR..  (2012)  PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.,  55  (20): [PMID:22924688] [10.1021/jm300847w]

2. Safina BS, Sweeney ZK, Li J, Chan BK, Bisconte A, Carrera D, Castanedo G, Flagella M, Heald R, Lewis C, Murray JM, Nonomiya J, Pang J, Price S, Reif K, Salphati L, Seward EM, Wei B, Sutherlin DP..  (2013)  Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity.,  23  (17): [PMID:23867164] [10.1016/j.bmcl.2013.06.052]

3. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data